PriceTargets.com logo

NASDAQ:ONS - Oncobiologics Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$1.82 As of 04/16/2021 01:00 AM ET
▼ -0.08 (-4.21%)
Get New Oncobiologics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ONS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ONS

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Oncobiologics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $1.82.
N/A
The current consensus among 0 investment analysts is to n/a stock in Oncobiologics. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/27/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/25/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/24/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/23/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/21/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/19/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/20/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/19/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/29/2018BarclaysDowngradeOverweight ➝ Equal WeightLow
i
4/13/2017Cantor FitzgeraldReiterated RatingBuy$15.00Low
i
4/12/2017Jefferies Financial GroupReiterated RatingHold$3.00High
i
3/7/2017Jefferies Financial GroupDowngradeBuy ➝ HoldN/A
i
6/7/2016Cantor FitzgeraldReiterated RatingBuy$15.00N/A
i
6/7/2016BarclaysReiterated RatingOverweight$11.00N/A
i
(Data available from 4/19/2016 forward)
Oncobiologics logo
Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification, development, manufacture, and commercialization of ONS-5010/LYTENAVA as the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, including wet AMD, DME and BRVO. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in South Brunswick, NJ.
Read More

Today's Range

Now: $1.82
$1.75
$1.89

50 Day Range

MA: $2.15
$0.72
$7.40

52 Week Range

Now: $1.82
$0.57
$1.53

Volume

923,733 shs

Average Volume

69,024 shs

Market Capitalization

$131.40 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Oncobiologics?

The following sell-side analysts have issued reports on Oncobiologics in the last year:
View the latest analyst ratings for ONS.

What is the current price target for Oncobiologics?

0 Wall Street analysts have set twelve-month price targets for Oncobiologics in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Oncobiologics in the next year.
View the latest price targets for ONS.

What is the current consensus analyst rating for Oncobiologics?

Oncobiologics currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for ONS.

What other companies compete with Oncobiologics?

Other companies that are similar to Oncobiologics include Precision BioSciences, Aptose Biosciences, Freeline Therapeutics, AVROBIO, Gritstone Oncology, Jounce Therapeutics, Opthea, Lineage Cell Therapeutics, SQZ Biotechnologies, Fusion Pharmaceuticals, Innate Pharma, Innate Pharma, Outlook Therapeutics, Cardiff Oncology and Surface Oncology.

How do I contact Oncobiologics' investor relations team?

Oncobiologics' physical mailing address is 7 CLARKE DRIVE, CRANBURY NJ, 08512. The company's listed phone number is (609) 619-3990 and its investor relations email address is [email protected] The official website for Oncobiologics is www.oncobiologics.com.